SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that members of leadership will participate in the following upcoming investor conferences:
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations and is committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Health Catalyst Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.
Health Catalyst Media Contact:
Amanda Flanders
Senior Vice President, Marketing and Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.80 |
Daily Change: | 0.06 1.60 |
Daily Volume: | 559,080 |
Market Cap: | US$231.230M |
May 07, 2025 February 26, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load